M. Melnikova, V. Ruzov, R. K. Gimaev, A. M. Vorobev, A. Ibrahim
{"title":"梗死后时期血管紧张素II水平与心脏结构参数及预后的关系","authors":"M. Melnikova, V. Ruzov, R. K. Gimaev, A. M. Vorobev, A. Ibrahim","doi":"10.32000/2072-1757-2023-1-43-47","DOIUrl":null,"url":null,"abstract":"The purpose — to determine the level of angiotensin II early after myocardial infarction and its relationship with cardiac structural parameters, as well as the role of this biomarker in the occurrence of recurrent cardiovascular events. Material and methods. The study included 96 patients with new onset myocardial infarction who underwent coronary revascularization procedures. Serum angiotensin II levels were measured on days 30–40. Patients were divided into groups according to the value of this biomarker. Echocardiography was performed on all patients included in the study on days 30–40 after myocardial infarction; the risk of repeat cardiovascular events was assessed in a 12-month follow-up. Results. Against the background of routine treatment (including angiotensin-converting enzyme inhibitors) early after infarction, according to the recommendations of the Ministry of Health of the Russian Federation, 10 patients had the elevated angiotensin II level. Significant differences in LV wall thickness and myocardial mass were observed in patients with elevated angiotensin II levels; elevated angiotensin II at 30 to 40 days was not associated with the risk of repeat cardiovascular events in a 12-month follow-up. Conclusions. Elevated angiotensin II levels are associated with increased left ventricular wall thickness but do not affect the risk of repeat cardiovascular events.","PeriodicalId":9821,"journal":{"name":"中国实用医药","volume":"117 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Relationship between angiotensin II level and the structural parameters of heart and prognosis in the post-infarction period\",\"authors\":\"M. Melnikova, V. Ruzov, R. K. Gimaev, A. M. Vorobev, A. Ibrahim\",\"doi\":\"10.32000/2072-1757-2023-1-43-47\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The purpose — to determine the level of angiotensin II early after myocardial infarction and its relationship with cardiac structural parameters, as well as the role of this biomarker in the occurrence of recurrent cardiovascular events. Material and methods. The study included 96 patients with new onset myocardial infarction who underwent coronary revascularization procedures. Serum angiotensin II levels were measured on days 30–40. Patients were divided into groups according to the value of this biomarker. Echocardiography was performed on all patients included in the study on days 30–40 after myocardial infarction; the risk of repeat cardiovascular events was assessed in a 12-month follow-up. Results. Against the background of routine treatment (including angiotensin-converting enzyme inhibitors) early after infarction, according to the recommendations of the Ministry of Health of the Russian Federation, 10 patients had the elevated angiotensin II level. Significant differences in LV wall thickness and myocardial mass were observed in patients with elevated angiotensin II levels; elevated angiotensin II at 30 to 40 days was not associated with the risk of repeat cardiovascular events in a 12-month follow-up. Conclusions. Elevated angiotensin II levels are associated with increased left ventricular wall thickness but do not affect the risk of repeat cardiovascular events.\",\"PeriodicalId\":9821,\"journal\":{\"name\":\"中国实用医药\",\"volume\":\"117 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国实用医药\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.32000/2072-1757-2023-1-43-47\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实用医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32000/2072-1757-2023-1-43-47","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Relationship between angiotensin II level and the structural parameters of heart and prognosis in the post-infarction period
The purpose — to determine the level of angiotensin II early after myocardial infarction and its relationship with cardiac structural parameters, as well as the role of this biomarker in the occurrence of recurrent cardiovascular events. Material and methods. The study included 96 patients with new onset myocardial infarction who underwent coronary revascularization procedures. Serum angiotensin II levels were measured on days 30–40. Patients were divided into groups according to the value of this biomarker. Echocardiography was performed on all patients included in the study on days 30–40 after myocardial infarction; the risk of repeat cardiovascular events was assessed in a 12-month follow-up. Results. Against the background of routine treatment (including angiotensin-converting enzyme inhibitors) early after infarction, according to the recommendations of the Ministry of Health of the Russian Federation, 10 patients had the elevated angiotensin II level. Significant differences in LV wall thickness and myocardial mass were observed in patients with elevated angiotensin II levels; elevated angiotensin II at 30 to 40 days was not associated with the risk of repeat cardiovascular events in a 12-month follow-up. Conclusions. Elevated angiotensin II levels are associated with increased left ventricular wall thickness but do not affect the risk of repeat cardiovascular events.